Target Audience and Goal Statement
This educational activity is intended for an international audience of non-US healthcare professionals, specifically psychiatrists,
primary care physicians, and neurologists involved in the management of patients with major depressive disorder (MDD).
The goal of this activity is to discuss some of the scales and neuropsychological tests used to measure depression and cognitive
function in patients with MDD and their relevance in interpreting patient outcomes and clinical data on treatments.
Upon completion of this activity, participants will be able to:
- Identify scales for measuring cognitive function in patients with major depressive disorder.
- Discuss the potential for use of scales to measure patient symptoms and outcomes in daily clinical practice.
- Recognize the relevance of measurement scales in determining response to treatment in clinical trials
Disclosures
WebMD Global requires each individual who is in a position to control the content of one of its educational activities to
disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.
Moderator
-
John Harrison, CSci, CPsychol
Honorary Senior Lecturer, Department of Medicine, Imperial College London, London, United Kingdom
Disclosures
Disclosure: John Harrison, CSci, CPsychol has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Anavex Life Sciences Corp.; AstraZeneca Pharmaceuticals LP;
Avraham Pharmaceuticals; AXON; Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bracket Global; Catenion; CRF
Health; Dendron UK; Eisai Co., Ltd; Eli Lilly and Company; EnVivo Pharmaceuticals; Enzymotec Ltd.; ePharmaSolutions; Heptares;
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kyowa Hakko Kirin Co., Ltd.; Lundbeck, Inc.; MedAvante; Mind
Agilis; MyCognition; Neurocog; Novartis Pharmaceuticals Corporation; Nutricia; Orion Corporation; Pfizer Inc.; Prana Biotechnology;
Pricespective; ProPhase; ProStrakan, Inc.; Reviva Pharmaceuticals Inc; Roche; SERVIER; Shire; Takeda Pharmaceuticals North
America, Inc.; TCG; TransTech Pharma; UCB Pharma, Inc.; Velacor
Served as a speaker or a member of a speakers bureau for: Lundbeck, Inc.
Owns stock, stock options, or bonds from: NeurotrackOther:
Owns by a commercial interest: Metis Cognition Ltd;
Received Royalties: Oxford University Press & Blackwell Publishers
Panelists
-
Larry Culpepper, MD, MPH
Professor of Family Medicine, Boston University School of Medicine; Staff Physician, Boston Medical Center, Boston, Massachusetts,
United States
Disclosures
Disclosure: Larry Culpepper, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Forest Laboratories, Inc.; H. Lundbeck A/S; Merck
& Co., Inc.; Shire; Takeda Pharmaceuticals Inc.; Elsevier B.V.
Owns stock, stock options, or bonds from: M3 (My Mood Monitor)
Received royalties from: UpToDate, Inc.; Oxford University Press
Received payment for serving as Editor-in-Chief of the Primary Care Companion for CNS Disorders
-
Guy M. Goodwin, FMedSci
W. A. Handley Professor of Psychiatry, Department of Psychiatry, University of Oxford, Oxford, United Kingdom
Disclosures
Disclosure: Guy M. Goodwin, FMedSci has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Otsuka Pharmaceutical Co., Ltd.; SERVIER;
Sunovion Pharmaceuticals Inc.; Teva Neuroscience, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; GlaxoSmithKline;
Lundbeck, Inc.; Otsuka Pharmaceutical Co., Ltd.; SERVIER
Received grants for clinical research from: SERVIER
Owns stock, stock options, or bonds from: P1vital
-
Raymond W. Lam, MD
Professor and Associate Head for Research, Department of Psychiatry, University of British Columbia; Director, Mood Disorders
Centre, UBC Hospital, Vancouver Coastal Health; Executive Chair, Canadian Network for Mood and Anxiety Treatments (CANMAT),
Vancouver, British Columbia
Disclosures
Disclosure: Raymond W. Lam, MD has disclosed the following relevant financial relationships: :
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson & Johnson Pharmaceutical
Research & Development, L.L.C.; Lundbeck, Inc.; Mochida; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Lundbeck, Inc.; Otsuka Pharmaceutical
Co., Ltd.; SERVIER
Received grants for clinical research from: Bristol-Myers Squibb Company; Lundbeck, Inc.; Pfizer Inc.; St. Jude Medical
Received book royalties from Cambridge University Press, Oxford University Press, Informa Press
Steering Comittee
-
Guy M. Goodwin, FMedSci
As listed above.
-
John Harrison, CSci, CPsychol
As listed above.
-
Siegfried Kasper, MD
Professor and Chair, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Disclosures
Disclosure: Siegfried Kasper, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Angelini; Bristol-Myers Squibb Company; Eli Lilly and Company GlaxoSmithKline; Janssen
Pharmaceuticals; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon International Inc.; Pfizer Inc.; Pierre Fabre; Schwabe
Pharmaceuticals; Sepracor Inc.; SERVIER; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Angelini; AOP Orphan Pharmaceuticals AG; AstraZeneca Pharmaceuticals
LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon
International Inc.; Pierre Fabre; Schwabe Pharmaceuticals; SERVIER; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Lundbeck, Inc.
-
Raymond W. Lam, MD, FRCPC
As listed above.
-
Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, University of Toronto; Head of the Mood Disorders Psychopharmacology Unit, University
Health Network, Toronto, Ontario, Canada
Disclosures
Disclosure: Roger S. McIntyre, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company;
GlaxoSmithKline; Janssen-Ortho Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Organon Pharmaceuticals USA Inc.; Pfizer Inc.; Shire
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho
Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Pfizer Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck,
Inc.; Pfizer Inc.; Shire
-
David J. Nutt, MD, PhD
Edmund J Safra Professor of Neuropsychopharmacology; Head of the Centre for Neuropsychopharmacology, Imperial College London,
London, United Kingdom
Disclosures
Disclosure: David J. Nutt, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Lundbeck, Inc.; Merck Sharp & Dohme Corp.
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline;
Janssen Pharmaceuticals, Inc.; NalPharm; Otsuka Pharmaceutical Co., Ltd.
Received grants for clinical research from: GlaxoSmithKline; Lundbeck, Inc.
Owns stock, stock options, or bonds from: P1vital Other:
Received writing fees: Reckitt Benckiser
Editor
Content Reviewer
-
Nafeez Zawahir, MD
CME Clinical Director
Disclosures
Disclosure: CME Clinical Director Nafeez Zawahir, MD, has disclosed no relevant financial relationships.
Accreditation Statements
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information about your
eligibility to claim credit, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must
complete the activity online during the credit eligibility period that is noted on the title page.
Follow these steps to claim a credit certificate for completing this activity:
- Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures,
read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test
and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this
activity, we will issue you a CPD credit certificate.
- Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits
will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the
tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.
We encourage you to complete an Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
